Corporate | 6 January 2010 11:41
Biotest AG / Disposal
06.01.2010
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Sale of Medical Diagnostics business to Bio-Rad completed
- Transaction has been successfully closed today after clearance of merger
control authorities was given
- Biotest's Microbiology business in the US now with Biotest Microbiology
Corp. Rockaway, NJ, USA
Dreieich, 6. January 2010. All relevant European merger control authorities
approved the sale of major parts of Biotest's Medical Diagnostics segment
to Bio-Rad Laboratories, Inc. (Hercules, CA/USA). Biotest AG and Bio-Rad
Laboratories, Inc. therefore closed the deal which had been agreed on 23
October 2009 today.
All shares of Biotest Medical Diagnostics GmbH (Dreieich) and Biotest
Diagnostics Corporation (Rockaway/USA) had been transferred to Bio-Rad. In
addition, the transaction comprises the transfusion and transplantation
diagnostic businesses of Biotest Group's international subsidiaries under
an asset deal.The purchase price amounts to EUR 45 million.
Bio-Rad Laboratoires, Inc. is a multinational manufacturer and distributor
of life science research and clinical diagnostic products.
The Biotest Diagnostics Corporation had also handled the Microbiology
business of Biotest Group in the United States up to now. This part of the
business has been spun of to the new subsidiary Biotest Microbiology Corp.
This company is located on the same premises as the sold Biotest Medical
Diagnostics Corporation in Rockaway, NJ. The employees dedicated to the
Microbiology business and the contact dates for the Microbiology customers
will remain unchanged.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
fax: +49 (0) 6103 801-347
e-mail: investor_relations@biotest.de
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center
of scientific discovery for more than 50 years, manufacturing and
distributing a broad range of products for the life science research and
clinical diagnostic markets. The company is renowned worldwide among
hospitals, universities, major research institutions, as well as
biotechnology and pharmaceutical companies for its commitment to quality
and customer service. Founded in 1952, Bio-Rad is headquartered in
Hercules, California, and serves more than 85,000 research and industry
customers worldwide through its global network of operations. The company
employs over 6,500 people globally and had revenues exceeding $1.7 billion
in 2008. For more information, visit www.bio-rad.com.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
tel.+1:510-724-7000
e-mail: investor_relations@bio-rad.com
06.01.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------